Atlas Pearls Ltd Overview
Atlas Pearls is a vertically integrated, Indonesia-based producer of white and silver South Sea pearls cultivated in the gold-lip/silver-lip Pinctada maxima oyster, and one of the very few publicly listed pure-play pearl producers globally. It controls the full biological value chain — broodstock genetics, hatcheries, nurseries, nucleation (seeding), multi-year grow-out across eight farm locations and harvesting — and monetises output primarily through its own regular auctions in Kobe, Japan, supplemented by private wholesale sales, value-add programmes and a small retail/online channel. Annual harvests have been remarkably stable at roughly 600,000–630,000 pearls, so earnings are driven overwhelmingly by realised price per pearl, which is a function of quality mix and luxury-goods demand in Japan, Hong Kong and mainland China. After a record FY2024 (NPAT A$31.5m) on cyclical price highs, FY2026 delivered a statutory loss as pearl quality and prices fell, testing management's FY30 roadmap to lift production 30–50%.
What the company does
Atlas Pearls produces South Sea pearls. In its own words (FY2026 Annual Report, Directors' Report §3), the Company produces South Sea pearls with pearling operations throughout Indonesia and sells them through a multi-channel distribution network; it describes itself as one of the world's largest producers and distributors of white and silver South Sea pearls, operating eight farming locations in Indonesia, employing more than 1,200 people, and harvesting 619,598 pearls in FY2026 (FY2025: 621,458). The stated vision is to be the global leader in producing the world's finest South Sea pearls; the mission emphasises sustainable, respectful production that cares for environment, people, communities and shareholders.
Production model (the biological value chain)
The pearl production cycle is long and capital-tied. Atlas's process, as described across the FY2025 and FY2026 annual reports, runs as follows:
-
Broodstock and genetics — selective breeding through a "breeding matrix" programme intended to raise inherent pearl quality (lustre, size, colour, surface).
-
Hatchery — spat (larval oysters) produced at Company hatcheries (North Bali, Lembata, West Lembata), now supported by probiotic-assisted processes.
-
Nursery — juvenile oysters raised for roughly two years until large enough to nucleate. Since FY2025 a growing share of nursery activity has been outsourced to joint-venture nursery partners who grow Atlas-genetics spat on Atlas's behalf (capital-light, geographically diversified).
-
Nucleation (seeding) — technicians implant a nucleus and mantle tissue; FY2026 saw a record number of oysters seeded. Oysters that reject the nucleus were historically sold cheaply; from FY2026 these are selectively re-seeded.
-
Grow-out — nucleated oysters cultured at grow-out farms (notably Alyui Bay in West Papua and Alor), traditionally for 24 months post-seeding; Alyui is moving ~80% of production to an 18-month cycle in FY2027, Alor ~20%.
-
Harvest and grading — pearls harvested, graded using an internal Quality Index Score / Index Point system (shape, grade, size, colour), and allocated to channels.
-
Sale — Kobe auctions (roughly quarterly), private wholesale appointments, value-add wholesale (strands, matched sets), retail showrooms/online, and by-product sales (mother-of-pearl shell, oyster meat, low-grade/reject pearls).
A new purpose-built logistics and harvesting vessel, the Atlas Pearl, was undergoing sea trials at the time of the FY2026 report and was scheduled to sail to North Bali in September 2026, with its first pearl harvest planned for October 2026.
Revenue model
| Revenue type | Description | Disclosure |
|---|---|---|
| Product sales — loose pearls (auction) | Kobe auctions, roughly 4 per year, sold to international wholesalers | Majority of revenue; average auction price FY2026 A$63/pearl vs A$87 in FY2025 (FY2026 AR) |
| Product sales — loose pearls (private) | Private appointments with wholesale customers | Material and growing; e.g. ~A$1.35m sold privately in Apr–May 2026 (June 2026 auction update) |
| Product sales — value-add and retail | Strands, jewellery, farm showrooms, Bali retail, online | Small; not separately quantified in FY2026 |
| By-products | Shell, low-grade/reject pearls, other | FY2026 by-product cash receipts A$1.18m (cash flow statement) |
| Services / subscription / licensing | — | Not applicable |
All revenue is recognised at a point in time as sale of goods (FY2026 AR, Note 3). The business is therefore 100% product revenue, with no recurring contracted revenue.
Customer types and end-markets
Customers are predominantly international pearl wholesalers and jewellery manufacturers attending the Kobe auctions — historically Japanese, Hong Kong and mainland Chinese buyers — plus private wholesale clients and a small number of retail consumers. Concentration has been significant: in FY2025 one customer accounted for A$14.3m of revenue (~32%), attributed to the Australian segment; in FY2026 no single customer exceeded 10% of revenue (FY2026 AR, Note 2.1). End-demand is the global luxury jewellery market, with China/Hong Kong and Japan the dominant consumption and trading hubs.
Independent characterisation
Atlas is best understood as an aquaculture commodity producer with luxury-goods price exposure: volume is quasi-fixed in the short term (two-to-four-year biological lead times), costs are largely fixed (labour, vessels, remote sites), and price per pearl swings sharply with both harvest quality and Asian luxury sentiment. This produces extreme operating leverage — revenue rose 53% in FY2024 while NPAT rose 246%; revenue fell 42% in FY2026 and the Company swung to a A$7.9m loss. Reported earnings are further amplified by AASB 141 Agriculture fair-value revaluation of oysters, which added A$13.9m in FY2024 and subtracted A$7.9m in FY2026.
Strategy
Stated strategy
The FY30 Strategic Roadmap (introduced with FY2025 results, refined in FY2026, and now being extended to FY32) rests on four pillars: (1) Quality Operations; (2) Innovation; (3) People & Culture; (4) Customers & Stakeholders. Management's overarching objective is to grow pearl production, improve quality and reduce the real cost of production through operational excellence, scale and innovation. Under Quality Operations, initiatives are consolidated into three business-wide programmes: the Pearl Improvement Plan, the Revised Operating Model, and Revenue Diversification Opportunities.
Medium-term targets
| Target / guidance | Detail | Source |
|---|---|---|
| Production capacity | +30% to +50% by FY2030 | FY2025 4E / AR |
| Alyui site output | From ~180k to >400k pearls p.a. over medium-to-long term (expansion plus 18-month cycle) | FY2026 AR |
| Throughput uplift from 18-month cycle | ~25% long-term increase at sites adopting it, at optimal stocking | FY2026 AR |
| Re-seeding programme | A$1.0–1.5m additional annual earnings from FY2029 | FY2026 AR |
| Dividend policy | Target payout of 50% of normalised NPAT | FY2024/FY2025 reporting |
| Formal revenue/earnings guidance | None provided | — |
Initiative register (last 24 months)
| Initiative | Timing | Scope and status |
|---|---|---|
| JV nursery partner network | FY2025–ongoing | Long-term JV partners grow Atlas-genetics spat; expanded in FY2026; Company has mapped best-performing nursery locations to guide future own-nursery decisions |
| Organic capacity expansion | FY2026 | Alor +50k, Alyui +25k nucleated; West Lembata +30k and Pungu +50k nucleated-equivalent spat capacity |
| Alyui lease expansion | Approval FY2026; build from H2 FY2027 | 7 blocks approved, 5 progressing |
| Cultivation-cycle optimisation | FY2027 | 18-month cycle at ~80% of Alyui and ~20% of Alor |
| Genetics and hatchery programme | Ongoing | Breeding matrix; probiotic-supported hatchery; first benefits appearing in early FY2027 harvests |
| North Bali mortality response | H2 FY2026 | Hatchery output redirected; oyster transfers into North Bali suspended; environmental monitoring expanded to all sites |
| Re-seeding of rejected oysters | FY2026 | Selectively reintroduced |
| Atlas Pearl logistics vessel | Commissioning Sep–Oct 2026 | Optimises shell transfers and harvesting logistics |
| Site portfolio optimisation | FY2026 | Sumba mothballed; ~20 greenfield sites in pipeline |
| Sales strategy | FY2024–ongoing | Multi-channel model to reduce auction and customer concentration; data-driven pricing; redirecting suitable inventory to value-add and retail |
| Lobster aquaculture pilot | FY2027 | Grow-out trial to test commercial viability for export to Asian markets |
| Multi-species hatchery licensing | FY2026 | Government licensing approvals received |
| Government & Stakeholder Engagement Plan | FY2026 | Formal framework aligned with Indonesia's Blue Economy Roadmap 2023–2045 |
| Leadership | FY2026 | Dedicated COO role created (Mat Pullen) |
| HSE | FY2026–ongoing | Progress toward ISO 45001; Just Culture framework; ICAM investigations |
| Sustainability Framework | FY2026 | Three pillars, 13 pathways, six KPIs; GRI-aligned FY2026 Sustainability Report |
| Cost programme | — | No quantified cost-reduction programme with targets disclosed |
Products & Services
Atlas is a single-product-family business; the catalogue below is organised by product category and channel rather than by segment, because both segments sell the same products.
Launch/version years: the loose-pearl business has operated since the 1990s; Kobe auction channel since May 2012; Employee-facing retail showrooms reopened progressively from FY2023–FY2024 after the pandemic; re-seeding reintroduced FY2026; lobster pilot FY2027. No flagship branded sub-lines with separate disclosure exist.
Product Portfolio
| Product / offering | Description | Key specifications | Target customer | Channel | Pricing disclosure |
|---|---|---|---|---|---|
White South Sea loose pearls (first-operation) | Core product cultivated in Pinctada maxima | Historically focused on 10–14mm diameter (per former MD); graded by shape, surface, lustre, size and colour via internal Index Point system | International wholesalers, jewellery manufacturers | Kobe auctions; private appointments | Auction averages: Sep 2025 A$60; Dec 2025 A$80; Mar 2026 A$66; Jun 2026 A$55; Sep 2026 A$75.90 per pearl |
Silver South Sea loose pearls | Silver-toned variant from the same species | As above | As above | As above | — |
Re-seeded (second-operation) pearls | New from FY2026: oysters that rejected their first nucleus are re-seeded rather than sold off | Typically lower quality than first-operation pearls | Wholesale | Auction/private | Management estimate: A$1.0–1.5m additional annual earnings from FY2029 |
Low-grade, C2 and reject pearls | Lower-quality output | Below commercial auction grades | Bulk wholesale, Indonesian buyers | Private/bulk | FY2026: 273k pearls sold at average A$3.45 (FY2025: 149k at A$6.90) |
Keshi pearls | Non-nucleated pearls formed as by-product | Irregular shapes | Wholesale and jewellery | Wholesale; jewellery (e.g. keshi studs) | — |
Value-add wholesale programmes | Strands, matched pairs, curated lots | Matched size/colour sets | Wholesalers, retailers | Private wholesale | Not disclosed; management prioritising redirection of suitable inventory into this channel |
Atlas Pearls jewellery | Pearl jewellery designed/manufactured in-house (examples historically marketed include pendants, studs, rings, bracelets — e.g. cage pendant, keshi studs, vine ring, double pearl bracelet, paved diamond pendant) | Silver/gold settings with South Sea and keshi pearls | Retail consumers, tourists | Bali retail, farm showrooms (e.g. Pungu, reopened FY2024), online store | Retail list prices not disclosed in filings |
Mother-of-pearl shell and by-products | Shell and other oyster by-products | — | Industrial/craft buyers | Indonesia | FY2026 cash receipts A$1.18m; FY2025 A$1.52m |
Lobster aquaculture (pilot) | Pilot grow-out of spiny lobster from Indonesian wild-caught seed (puerulus) for export to Asian markets | Trial covers husbandry, feed formulation, feed conversion and growth | Asian seafood markets | Not yet commercial | Pilot commenced FY2027; business case pending |
Multi-species hatchery | Licensing approvals received for multi-species hatchery and farming | — | — | — | Pre-commercial |
“—” = not publicly disclosed.
Financial Narrative
Income statement
Sources: FY2026 AR §5.1, §14.2.2 and financial statements; FY2024 AR; FY2023 AR; FY2026 AR revenue/EBITDA chart for FY2022–FY2023 revenue and EBITDA; S&P Global (StockAnalysis) for FY2022–FY2023 PBT/tax and gross profit. Discrepancies: (i) FY2022 revenue is A$20.6m in the FY2026 AR chart but A$21.51m in S&P data (likely inclusion of other income); (ii) FY2025 PBT is A$26.97m audited vs A$27.31m in S&P data; (iii) FY2025 NPAT was headlined as A$21.9m in the FY2025 Appendix 4E and media, but the audited income statement (reproduced as FY2026 comparatives) shows A$21.57m — the A$21.90m figure equals NPAT plus A$0.33m actuarial gains recognised in other comprehensive income; (iv) the FY2025 announcement described FY2024 dividends as 1.85c, which is the cash-paid figure, while the declared-for-year figure was 2.5c (1.5c March 2024 + 1.0c September 2024).
Margins and growth
Derived revenue CAGR: FY2022–FY2025 ≈ 29.0% p.a.; FY2022–FY2026 ≈ 5.8% p.a. (derived).
Commentary. The five-year profile is a full price cycle in miniature. FY2022–FY2024 margins expanded dramatically because pearl prices roughly doubled (record A$103/pearl in H1 FY2024) against a largely fixed farm cost base, and because rising oyster valuations produced large non-cash AASB 141 gains (A$13.9m in FY2024 alone, explaining why pre-tax margin approached 95%). FY2025 revenue held up (+6%) only because volume sold rose 24% to 593k pearls while price normalised (H1 FY2025 average A$65 vs A$103 a year earlier); normalised EBITDA fell 18%. FY2026 then combined three negatives: (1) quality index down 18% (15% excluding the Sumba trial site); (2) softer luxury demand and FX headwinds, cutting the auction average to A$63 from A$87; and (3) a mix shift to low-grade pearls (273k units at A$3.45). The swing in the biological revaluation from +A$5.9m to −A$7.9m and a A$2.6m impairment (Note 11, loans receivable) turned a still-positive normalised EBITDA of A$5.8m into a A$7.9m statutory loss. The Chairman notes non-cash losses of A$11.9m in FY2026 versus non-cash net gains of A$4.1m in FY2025.
Normalised EBITDA reconciliation (company-reported)
Source: FY2026 AR §5.1. Normalised EBITDA is non-IFRS and unaudited.
FY2026 operating cost base
Administration, finance and marketing combined fell A$0.9m to A$8.0m (FY2026 AR §5.2.1), showing modest cost discipline but far less flex than the A$18.5m revenue decline. FY2025 other income was inflated by a A$1.95m FX gain.
Balance sheet
Sources: FY2026 AR statements and §5.2; S&P Global for FY2022–FY2023 (and FY2024 sub-lines). S&P classifies non-current biological assets within PP&E, so FY2022–FY2024 biological and PP&E splits are not shown. FY2025 biological assets were also summarised in secondary coverage as A$42.77m versus A$43.01m in audited statements (small variance, possibly a classification of a sub-line).
Commentary. The balance sheet is conservatively financed: effectively no financial debt since FY2023 (after retiring the Boneyard facility), an undrawn A$2.5m overdraft, and equity funding 84% of assets in FY2026. The quality of assets, however, is dominated by biological assets (A$37.0m, 58% of total assets at 30 Jun 2026) whose carrying value is a Level-3 fair-value estimate sensitive to assumed future pearl prices, quality and mortality — the primary source of earnings volatility. Cash fell A$13.3m in FY2026 as operating cash flow went to roughly zero while the Company sustained capex (A$4.4m PP&E, A$0.65m intangibles), dividends (A$6.1m) and a further A$1.2m loan to PT Cahaya Bali. Equity fell A$17.1m, driven by the loss, dividends and a A$3.4m adverse FX translation (weaker Indonesian rupiah).
Cash flow
FY2022 FCF from S&P Global; other years from audited cash flow statements (FY2024 AR; FY2026 AR). Commentary: FY2026's near-zero operating cash flow was depressed by A$5.4m of income tax paid — largely tax on the strong FY2025 result — while receipts from pearl sales fell to A$24.3m from A$43.2m. On a pre-tax basis, operating cash generation was ~A$5.3m, broadly consistent with normalised EBITDA. A current tax asset of A$1.57m at 30 Jun 2026 suggests some tax refund support in FY2027.
Ratios
ROIC is not presented: with negligible debt and earnings dominated by fair-value adjustments, a conventional ROIC calculation would largely duplicate ROE and would not be meaningful. Cash conversion cycle is not meaningful for a biological-asset business with a two-to-four-year production cycle; inventory of graded pearls (A$3.8m) plus biological assets (A$37.0m) relative to farm costs (A$11.6m) implies capital is tied up for roughly three years of farm spend.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment external revenue (AUD Mn)
| Segment external revenue (AUD Mn) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Australia | — | 39.77 | 20.60 |
Indonesia | — | 4.51 | 5.18 |
Total revenue from contracts with customers | 41.71 | 44.27 | 25.78 |
Segment gross revenue incl. inter-segment (AUD Mn)
| Segment gross revenue incl. inter-segment (AUD Mn) | FY2025 | FY2026 |
|---|---|---|
Australia total segment revenue | 39.77 | 20.60 |
Indonesia total segment revenue | 24.99 | 20.82 |
Inter-segment eliminations | -20.49 | -15.64 |
Segment normalised EBITDA (AUD Mn)
| Segment normalised EBITDA (AUD Mn) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Australia | — | 16.32 | 3.82 |
Indonesia | — | 2.28 | 1.95 |
Group normalised EBITDA | 22.63 | 18.60 | 5.77 |
Segment adjusted net operating profit before tax (AUD Mn)
| Segment adjusted net operating profit before tax (AUD Mn) | FY2025 | FY2026 |
|---|---|---|
Australia | 15.69 | 4.78 |
Indonesia | 2.83 | -12.68 |
Revenue by Segment (%) and Segment Margins & Growth (%)
| Derived metric (%) | FY2025 | FY2026 |
|---|---|---|
Australia share of external revenue | 89.8 | 79.9 |
Indonesia share of external revenue | 10.2 | 20.1 |
Australia YoY external revenue growth | — | -48.2 |
Indonesia YoY external revenue growth | — | 15.0 |
Australia EBITDA margin on external revenue | 41.0 | 18.5 |
Indonesia EBITDA margin on external revenue | 50.6 | 37.7 |
Income statement (AUD Mn)
| Income statement (AUD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from contracts with customers | 20.6 | 27.2 | 41.71 | 44.27 | 25.78 |
Gross profit (S&P Global basis) | 9.94 | 16.3 | 33.46 | 28.92 | — |
Revenue less farm costs and inventory changes (company P&L basis) | — | — | — | 30.45 | 14.19 |
Normalised EBITDA (company non-IFRS) | 4.3 | 9.8 | 22.63 | 18.60 | 5.77 |
Depreciation and amortisation | — | — | 0.32 | 0.44 | 0.45 |
Biological asset fair-value change (AASB 141) | — | — | 13.95 | 5.89 | -7.91 |
Impairment expense | — | — | 0 | 0 | 2.59 |
Profit before tax | 5.43 | 9.71 | 39.81 | 26.97 | -7.90 |
Income tax expense | 0.84 | 0.63 | 8.34 | 5.41 | 0.00 |
Net profit after tax | 4.59 | 9.09 | 31.47 | 21.57 | -7.90 |
EPS basic (A$ cents) | 1.08 | 2.14 | 7.37 | 4.93 | -1.80 |
EPS diluted (A$ cents) | — | — | — | 4.89 | -1.80 |
Dividends declared per share for the year (A$ cents) | 0 | 0.35 | 2.5 | 2.4 | 0.45 |
Dividends paid per share in the year (A$ cents) | 0 | 0 | 1.85 | 2.00 | 1.40 |
Margin / growth (%)
| Margin / growth (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue growth YoY | — | 32.0 | 53.3 | 6.1 | -41.8 |
Gross margin (S&P basis) | 48.3 | 59.9 | 80.2 | 65.3 | — |
Normalised EBITDA margin | 20.9 | 36.0 | 54.3 | 42.0 | 22.4 |
Pre-tax margin | 26.4 | 35.7 | 95.4 | 60.9 | -30.6 |
Net margin | 22.3 | 33.4 | 75.5 | 48.7 | -30.6 |
Income Statement
| Reconciliation item (AUD Mn) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Net profit after tax | 31.47 | 21.57 | -7.90 |
Interest (income)/expense | -0.26 | -0.37 | -0.20 |
Tax expense | 8.34 | 5.41 | 0.00 |
Depreciation and amortisation | 0.32 | 0.44 | 0.45 |
(Profit)/loss on disposal of assets | 0 | -0.33 | 0.01 |
Net FX (gain)/loss | 0.16 | -1.95 | 1.29 |
Agriculture standard revaluation (gain)/loss | -13.95 | -5.89 | 7.91 |
Changes in inventory (farm costs) (gain)/loss | -3.45 | -2.04 | 0.16 |
Write-down of pearls to net realisable value | 0 | 1.53 | 1.45 |
Loss on deconsolidation | 0 | 0.23 | 0 |
Impairment expense | 0 | 0 | 2.59 |
Normalised EBITDA | 22.63 | 18.60 | 5.77 |
Operating cost line (AUD Mn)
| Operating cost line (AUD Mn) | FY2025 | FY2026 |
|---|---|---|
Farm costs and changes in inventory | 13.82 | 11.59 |
Administration expenses | 8.35 | 7.51 |
Marketing expenses | 0.52 | 0.43 |
Other expenses | 1.41 | 2.53 |
Finance costs | 0.06 | 0.03 |
Other income | 2.73 | 0.37 |
Balance Sheet and Per-Share Data
| Balance sheet (AUD Mn, 30 June) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets | 31.52 | 40.07 | 69.85 | 85.89 | 64.02 |
Cash and cash equivalents | 3.00 | 7.85 | 17.62 | 20.21 | 6.95 |
Inventories | 3.17 | 3.32 | 8.97 | 6.42 | 3.80 |
Biological assets current | — | — | — | 18.45 | 15.95 |
Biological assets non-current | — | — | — | 24.56 | 21.07 |
Property plant and equipment | — | — | — | 7.87 | 7.34 |
Loans receivable (non-current) | — | — | — | 3.85 | 1.81 |
Borrowings short-term | 1.13 | 0 | 0 | 0 | 0.04 |
Borrowings long-term | 0 | 0 | 0 | 0 | 0 |
Lease liabilities total | 0.28 | 0.22 | 0.29 | 0.40 | 0.14 |
Net cash (cash less borrowings and leases) | 1.59 | 7.63 | 17.33 | 19.81 | 6.77 |
Total liabilities | 7.14 | 5.98 | 14.34 | 14.85 | 10.06 |
Shareholders' equity | 24.37 | 34.08 | 55.52 | 71.04 | 53.95 |
Goodwill | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0.02 | 0 | 0 | 0.86 | 1.30 |
Working capital (current assets less current liabilities) | 11.04 | 16.47 | 33.65 | 39.67 | 27.18 |
NTA per share (A$ cents) | — | — | 12.8 | 16.0 | 12.0 |
Shares on issue (millions) | 424.8 | 424.8 | 433.6 | 439.0 | 439.0 |
Cash flow (AUD Mn)
| Cash flow (AUD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow | — | 8.45 | 20.66 | 16.44 | -0.09 |
Capex — property plant and equipment | — | 2.16 | 1.85 | 3.23 | 4.45 |
Capex — intangibles | — | 0 | 0 | 0.91 | 0.65 |
Free cash flow (OCF less PP&E capex) | 3.38 | 6.29 | 18.81 | 13.21 | -4.53 |
Loans advanced to PT Cahaya Bali | — | — | — | 1.82 | 1.20 |
Dividends paid | 0 | 0 | 8.00 | 8.78 | 6.15 |
Share buybacks | 0 | 0 | 0 | 0 | 0 |
Income tax paid | — | 0.77 | 0.45 | 5.57 | 5.42 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE (% NPAT / average equity, derived) | 21.4 | 31.1 | 70.2 | 34.1 | -12.6 |
ROA (% NPAT / average assets, derived) | 15.4 | 25.4 | 57.3 | 27.7 | -10.5 |
Current ratio (x) | 3.16 | 5.20 | 5.35 | 6.66 | 8.17 |
Debt to equity incl. leases (x) | 0.06 | 0.01 | 0.01 | 0.01 | 0.00 |
Net debt to EBITDA (x, negative = net cash) | -0.37 | -0.78 | -0.77 | -1.07 | -1.17 |
Asset turnover (x revenue / average assets, derived) | 0.69 | 0.76 | 0.76 | 0.57 | 0.34 |
Normalised EBITDA interest coverage (x) | — | — | — | 326 | 171 |
Revenue by location of sale (AUD Mn)
| Revenue by location of sale (AUD Mn) | FY2025 | FY2026 |
|---|---|---|
Australia (international loose-pearl sales booked in Australia) | 39.77 | 20.60 |
Indonesia (local sales and by-products) | 4.51 | 5.18 |
Growth by location of sale (%)
| Growth by location of sale (%) | FY2026 |
|---|---|
Australia YoY | -48.2 |
Indonesia YoY | 15.0 |
Non-current assets excl. financial instruments and DTA (AUD Mn)
| Non-current assets excl. financial instruments and DTA (AUD Mn) | FY2025 | FY2026 |
|---|---|---|
Australia | 0.13 | 0.06 |
Indonesia | 34.34 | 32.33 |
Share price metric
| Share price metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Fiscal-year share price change (%) | 140 | 17 | 117 | 76 | -50 |
Share price at 30 June (A$ cents) | — | — | 9.1 | 16.5 | 8.3 |
Valuation Multiple Details
| Valuation multiple | Atlas Pearls | Listed peer set |
|---|---|---|
Market capitalisation | ~A$40m | No directly comparable listed peers |
Enterprise value (market cap less net cash A$6.8m) | ~A$33m | — |
P/E (FY2026) | Not meaningful (loss) | — |
P/E (FY2025 EPS 4.93c) | ~1.8x | — |
EV / normalised EBITDA (FY2026) | ~5.8x | — |
EV / normalised EBITDA (FY2025) | ~1.8x | — |
EV / Sales (FY2026) | ~1.3x | — |
P / Book (FY2026 equity A$53.95m) | ~0.74x | — |
P / NTA (12.0c) | ~0.76x | — |
Dividend yield (0.45c FY2026 final) | ~4.9% | — |
Dividend (A$ cents)
| Dividend (A$ cents) | Ex/payment timing | Amount | Franking |
|---|---|---|---|
FY2023 final | Ex 4 Sep 2023 / paid 26 Sep 2023 | 0.35 | 100% |
FY2024 interim/special | Ex 7 Mar 2024 / paid 22 Mar 2024 | 1.50 | 37.33% |
FY2024 final/special | Ex 12 Sep 2024 / paid 27 Sep 2024 | 1.00 | 100% |
FY2025 interim + special | Ex 6 Mar 2025 / paid 21 Mar 2025 | 1.00 (0.61 interim + 0.39 special) | 0% |
FY2025 final | Ex 4 Sep 2025 / paid 26 Sep 2025 | 1.40 | 100% |
FY2026 interim | — | 0 | — |
FY2026 final | Record 1 Sep 2026 / paid 25 Sep 2026 | 0.45 | 100% |
Dividends declared per share by fiscal year (A$ cents) | FY2022 | FY2023 | FY2024 |
Total declared | 0 | 0.35 | 2.5 |
Analyst Conclusions
Management guidance
No quantitative revenue or earnings guidance is given. Qualitative outlook (FY2026 AR): management enters FY2027 citing record seeding, expanded oyster supply channels, increased farm capacity and encouraging early-harvest quality, while acknowledging ongoing market uncertainty. Structural targets remain +30–50% production capacity by FY2030 and Alyui output >400k pearls p.a. in the medium-to-long term. Closing pearl inventory of 159k (vs 219k a year earlier) means FY2027 sales depend more heavily on in-year harvests.
Consensus
No sell-side coverage; consensus growth expectations not available.
Bull case
-
Quality inflection plus operating leverage: if early FY2027 quality gains (~20% above post-2022 average at Alor and Pungu) spread across the harvest, realised prices could recover toward the A$80+ auction levels seen as recently as December 2025, and FY2024 demonstrated that modest price gains translate into outsized EBITDA growth on a fixed cost base.
-
Volume growth is low-cost and visible: Alyui block approvals, 18-month cycles at the two farms producing ~two-thirds of output, record FY2026 seeding and re-seeding could lift harvests materially by FY2028–FY2030 without new equity.
-
Deep value with a clean balance sheet: at ~0.74x book and ~5.8x trough EV/EBITDA, with no debt and a still-positive dividend, the market price implies little recovery is expected.
Bear case
-
Structural price deterioration: value per index point has fallen ~37% from A$4.08 (Jun 2025) to A$2.56 (Sep 2026); if Chinese luxury demand and freshwater substitution keep pressure on South Sea pricing, quality gains may not restore revenue.
-
Biological supply risk: unresolved North Bali mortality, the Sumba failure and reliance on third-party JV nurseries could create a production gap in FY2028–FY2029, undermining the FY30 target.
-
Shrinking financial buffer and governance questions: cash fell to A$6.9m; operating cash flow was nil; the Company continues to fund a deconsolidated affiliate that required a A$2.6m impairment; discretionary bonuses in a loss year and an ASX disclosure query weigh on governance perception.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | What to watch |
|---|---|---|
| November 2026 Kobe auction | Nov 2026 | Average price, index score, $/index point (vs A$2.56), sell-through |
| 2026 AGM | Late 2026 | Remuneration vote given discretionary bonuses; board renewal |
| Atlas Pearl vessel first harvest | Oct 2026 | Operational efficiency, shell-transfer cost savings |
| H1 FY2027 results | Late Feb 2027 | Revenue recovery, return to statutory profit, interim dividend, cash balance |
| Quarterly Kobe auctions | Mar/Jun 2027 | Sustained quality improvement across sites |
| Alyui block expansion | H2 FY2027 | Commencement of 2–4 new blocks |
| North Bali environmental findings | FY2027 | Root-cause identification; resumption of transfers |
| Lobster pilot | FY2027 | Growth and feed-conversion data; business case |
| APA extension | FY2027 | Tax certainty on transfer pricing |
| PT Cahaya Bali exposure | Ongoing | Further advances or impairments |
Analyst verdict
Atlas Pearls is a genuinely distinctive listed asset — a vertically integrated, debt-free producer of roughly 620,000 South Sea pearls a year with thirty years of operating know-how in Indonesia — but it is also a textbook cyclical whose reported profits overstate stability on the way up and understate it on the way down. The five-year record is a complete price cycle: normalised EBITDA rose from A$4.3m (FY2022) to A$22.6m (FY2024) on record prices and then fell back to A$5.8m (FY2026) as quality slipped, buyers retreated and the grade mix deteriorated. Volume barely moved throughout; price and quality did all the work.
The investment question for the next two years is therefore narrow: can management restore quality and grow volume faster than the market erodes value per quality point? The evidence is mixed. On the positive side, record seeding, approved Alyui expansion, shorter cultivation cycles and early FY2027 quality readings around 20% above the recent average are concrete, low-capital levers, and the balance sheet, though thinner, carries no debt. On the negative side, the September 2026 auction showed that even a higher-quality lot achieved the lowest value per index point in the disclosed series; biological risk at North Bali remains unresolved; and governance signals — continued lending to a deconsolidated affiliate later impaired, above-formula bonuses in a loss year, and an ASX disclosure query — warrant vigilance from minority holders in a company where the largest shareholder group controls roughly a quarter of the register.
At around 0.74x book and below net tangible assets, the shares already discount a prolonged trough, and modest price recovery would generate disproportionate earnings uplift. We characterise Atlas as a high-risk, asymmetric recovery situation.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Background / education | Other current roles | FY2026 total remuneration (AUD) |
|---|---|---|---|---|---|
José Martins | Independent Non-Executive Chairman | Director 17 May 2023; Chairman 1 Jan 2025 | 25+ years finance executive; former CFO of Alliance Mining Commodities, Macmahon Holdings (ASX) and Ausdrill (now Perenti); Chartered Accountant (South Africa); BAcc (with distinction), University of the Witwatersrand; GAICD | NED, GenusPlus Group (since 2018); NED, Chilwa Minerals (since 20 Oct 2025) | 116,632 |
Timothy (Tim) Martin | Non-Executive Director (non-independent; associated with largest shareholder group) | 4 Feb 2013 | Executive Chairman of Coogee Chemicals (MD 2012–2015, Exec Chair from Jul 2015); prior packaged-food management; BA, MBA; Harvard OPM (2013); GAICD; former director PACIA and Kwinana Industries Council | None listed | 82,800 |
Cadell Buss | Independent Non-Executive Director | 1 Feb 2018 | Founder and MD of Chilwa Minerals (ASX: CHW); former CEO of stockbroker DJ Carmichael; former Project and Finance Director, Luso Global Mining; MBA and Master of Project Management (Murdoch University); GAICD | MD, Chilwa Minerals (since 1 Feb 2022) | 82,800 |
Executive Leadership Team
| Name | Title | Since | Background | FY2026 remuneration (AUD) |
|---|---|---|---|---|
Michael Ricci | Chief Executive Officer | 13 Jun 2022 | Prior roles not detailed in retrieved filings | Salary 406,304; STI 55,468; super 60,536; LSL 6,286; share-based 57,154; total 585,748 (FY2025: 562,934) |
Jean-Marie Rudd | Chief Financial Officer | 4 May 2024 | Prior roles not detailed in retrieved filings | Salary 247,191; STI 34,335; super 37,861; LSL 3,760; share-based 7,723; total 330,870 (FY2025: 304,833) |
Mat Pullen | Chief Operating Officer (new role) | Appointed during FY2026 (date not specified) | Indonesia-based; over five years in the business | Not a disclosed KMP in FY2026 |
Susan Park | Company Secretary | 19 Dec 2012 | 25+ years corporate finance/governance; MD of Park Advisory; BCom (UWA), ACA, F Fin, FGIA, FCG, GAICD | Not disclosed separately |
Major Shareholders
| Holder | Shares (m) | % of 439.0m | Notes |
|---|---|---|---|
Boneyard Investments Pty Ltd | 54.91 | 12.5 | Tim Martin-associated |
Chemco Superannuation Fund Pty Ltd (Chemco Super Fund No 2 A/C) | 46.13 | 10.5 | Martin-family associated |
TJM SF Pty Ltd (TJM Superannuation Fund A/C) | 2.03 | 0.5 | Tim Martin |
Tim Martin (direct) | 3.68 | 0.8 | — |
Tim Martin total relevant interest | 106.74 | 24.3 | Per FY2026 AR director interests |
HSBC Custody Nominees (Australia) | ~28.7 | ~6.5 | Nominee; figure from Motley Fool AU top-20 extract, date not confirmed |
Citicorp Nominees | ~26.4 | ~4.1–6.0 | Nominee; percentage inconsistent across sources |
Abermac Pty Ltd | 14.0 | 3.2 | Simply Wall St (secondary) |
Westwood Properties Pty Ltd | 8.0 | 1.8 | Secondary |
Morckstow Pty Ltd | 8.0 | 1.8 | Secondary |
Tingyao Xu | 5.16 | 1.2 | Secondary |
Queensridge Investments Pty Ltd (Gleeson Super Fund A/C) | 3.55 | 0.8 | Secondary |
Competitive Landscape
Key Competitors
| Competitor | Country | Segment overlap | Ownership | Relative positioning vs Atlas |
|---|---|---|---|---|
Paspaley Pearling Company | Australia | White South Sea pearls (Broome/NW Australia) | Private | Generally regarded as the world's largest and most prestigious South Sea producer; vertically integrated into luxury retail; higher-end positioning than Atlas |
Autore Group | Australia | South Sea pearls and jewellery | Private | Brand-led, jewellery-focused |
Cygnet Bay Pearls (Kimberley) | Australia | South Sea pearls, tourism | Private | Small, heritage/tourism niche |
Willie Creek Pearls / other Broome producers | Australia | South Sea pearls, retail/tourism | Private | Small producers; retail-tourism mix |
Jewelmer | Philippines | Golden South Sea pearls | Private | Dominant in gold-lip pearls; luxury brand integration |
Indonesian South Sea producers (numerous, incl. Japanese-affiliated farms) | Indonesia | White/silver/golden South Sea pearls | Private | Same production geography and auction buyer pool; Indonesia is the largest South Sea volume producer by count |
Robert Wan / Tahitian producers | French Polynesia | Tahitian (black) pearls | Private | Substitute colour category |
Mikimoto | Japan | Akoya and South Sea pearls; luxury retail | Private (K. Mikimoto & Co.) | Brand/retail leader; also a buyer of South Sea pearls |
Tasaki & Co. | Japan | Pearls and jewellery | Listing status should be verified | Brand-led jeweller; buyer and own-farm operator |
Chinese freshwater pearl producers (Zhuji cluster) | China | Freshwater pearls, including large high-lustre "Edison"-type | Private | Low-cost substitutes improving in size and quality — key long-run threat to smaller South Sea sizes |
Hong Kong/Japanese pearl wholesalers | HK/Japan | Downstream | Private | Customers that can also integrate upstream |
Competitor Detail
| Benchmark (latest fiscal year) | Atlas Pearls FY2026 |
|---|---|
Revenue | A$25.8m |
Revenue growth | −42% |
EBITDA margin | 22% (normalised) |
Recent Developments
--



